Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab (ARROW)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03553823
Recruitment Status : Active, not recruiting
First Posted : June 12, 2018
Last Update Posted : November 4, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The aim of this study is to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic plaques that remain active despite treatment with the non-selective IL-23 inhibitor ustekinumab (blocker of p40 subunit, shared by IL-12 and IL 23).

Condition or disease Intervention/treatment Phase
Chronic Plaque-type Psoriasis Procedure: Skin biopsies Phase 2

Detailed Description:
This is a 16-week, randomized, open-label, parallel-group, active-control, Phase 2a study comparing secukinumab 300 mg s.c. versus guselkumab 100 mg s.c. in subjects with plaque psoriasis who had an inadequate response to ustekinumab. Forty subjects will be randomized 1:1 and treated for 16 weeks. In each patient, a target active refractory skin plaque (TCS ≥6) will be described and biopsied at baseline and at study end. The objective of the study is to assess the superiority of secukinumab over guselkumab in achieving clear/almost clear status (TCS 0-2) of the target plaques and describe the molecular mechanisms behind this difference

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a 16-week, randomized, open-label, parallel-group, active-control study comparing secukinumab 300 mg s.c. versus guselkumab 100 mg s.c. in subjects with plaque psoriasis who had an inadequate response to ustekinumab.
Masking: Single (Outcomes Assessor)
Masking Description: Blinded outcome assessor will assess subjects on each visit for target plaque TCS, PASI, IGA, BSA, ppIGA, PSSI, NAPS.
Primary Purpose: Treatment
Official Title: A 16-week Randomized, Open-label, Multicenter Study to Assess the Superiority of Secukinumab Over Guselkumab in the Complete Treatment of Ustekinumab Resistant Psoriatic Plaques
Actual Study Start Date : January 14, 2019
Estimated Primary Completion Date : January 28, 2020
Estimated Study Completion Date : January 28, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: secukinumab
20 subjects with plaque psoriasis with an inadequate response to ustekinumab will self-administer 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
Procedure: Skin biopsies
At Baseline, two 6-mm punch biopsies will be taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy will be taken from the same area of the active plaque sampled at Baseline.

Active Comparator: Guselkumab
20 subjects with plaque psoriasis with an inadequate response to ustekinumab will self-administer guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
Procedure: Skin biopsies
At Baseline, two 6-mm punch biopsies will be taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy will be taken from the same area of the active plaque sampled at Baseline.




Primary Outcome Measures :
  1. Proportion of subjects whose plaque achieves "clear" or "almost clear" status (TCS = 0-2) [ Time Frame: 16 week ]
    To demonstrate the superiority of secukinumab over guselkumab in controlling clinical activity in psoriatic plaques resistant to treatment with ustekinumab


Other Outcome Measures:
  1. Change from Baseline to Week 16 in epidermal thickness of lesional skin biopsies [ Time Frame: Week 16 ]
    Compare the effect of secukinumab versus guselkumab on the microscopic morphology of the skin plaque

  2. Change from Baseline to Week 16 in the number of Ki-67/K-16 positive cells in skin biopsies [ Time Frame: Week 16 ]
    Compare the effect of secukinumab versus guselkumab on the microscopic morphology of the skin plaque

  3. Change from Baseline to Week 16 in the number of infiltrating cells expressing IL 17A and IL-23R of lesional skin biopsies and difference from the Baseline non-lesional skin biopsy [ Time Frame: Week 16 ]
    To compare the effect of secukinumab versus guselkumab on the number of IL-17A and IL-23R positive immune cells infiltrating the skin plaque

  4. Change from Baseline to Week 16 in the number of different immune cell types in the inflammatory infiltrate of lesional skin biopsies and difference from the Baseline non-lesional skin biopsy [ Time Frame: Week 16 ]
    compare the effects of secukinumab versus guselkumab on the composition of inflammatory infiltrate in the skin plaque



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Chronic plaque-type psoriasis considered inadequately controlled after treatment with ustekinumab according to the following criteria-:

  • Ustekinumab administered at a dose equal or higher than that on the label for at least 24 weeks. The last administration must be at least 12 weeks before randomization
  • absolute PASI score of 1-10 at Screening
  • Presence of at least 1 refractory skin plaque, defined by a TCS of at least 6 and severity score of at least 2 or 3 (moderate) for each individual item, with an area ≥ 10 cm2 at screening.

Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at Screening or Baseline
  • Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium) at Baseline
  • Previous treatment with more than one TNFα inhibitor or with IL-17A (including secukinumab), IL-17R or IL-23 (including guselkumab) inhibitors
  • Use of other investigational drugs within 4 weeks before enrolment, or within a period of 5 half lives of enrollment/initiation of the study treatment, whichever is longer
  • Ongoing use of prohibited treatments (see Section 6.2.2)
  • Known immunosuppression (e.g., AIDS) at Screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03553823


Locations
Layout table for location information
United States, Louisiana
Novartis Investigative Site
New Orleans, Louisiana, United States, 70112
United States, New Jersey
Novartis Investigative Site
East Windsor, New Jersey, United States, 08520
United States, New York
Novartis Investigative Site
Forest Hills, New York, United States, 11375
United States, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19140
United States, Texas
Novartis Investigative Site
Dallas, Texas, United States, 75230
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 1Z2
Canada, Quebec
Novartis Investigative Site
Verdun, Quebec, Canada, H4G 3E7
Germany
Novartis Investigative Site
Berlin, Germany, 13353
Novartis Investigative Site
Bochum, Germany, 44791
Novartis Investigative Site
Bonn, Germany, 53105
Novartis Investigative Site
Frankfurt, Germany, 60590
Novartis Investigative Site
Halle, Germany, 06108
Novartis Investigative Site
Hamburg, Germany, 22391
Novartis Investigative Site
Kiel, Germany, 24105
Novartis Investigative Site
Memmingen, Germany, 87700
Novartis Investigative Site
Selters, Germany, 56242
Sponsors and Collaborators
Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03553823    
Other Study ID Numbers: CAIN457A2403
First Posted: June 12, 2018    Key Record Dates
Last Update Posted: November 4, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Psoriasis
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Ustekinumab
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Dermatologic Agents